XAIR Beyond Air, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1641631 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY41.2%
TTM net income YoY9.1%
TTM EPS YoY168.8%
Revenue 3-yr CAGR201.8%
Net income 3-yr CAGR—
Margins
Gross margin10.0%
Operating margin-321.7%
Net margin-407.3%
FCF margin-259.0%
EBITDA margin-282.6%
Returns
ROE-369.6%
ROA-99.3%
ROIC (approx.)-1,404.8%
Asset turnover0.24x
Leverage & solvency
Liabilities / assets83.1%
Debt / equity0.00x
Current ratio3.67x
Interest coverage-4.95x
Cash quality & payout
Operating cash flow / net income0.59x
Accruals ratio-40.7%
Payout ratio—
Capex / revenue18.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 | FY20242024-03-31 | FY2023*2023-03-31 | FY20222022-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $7.68M | $3.71M | $1.16M | $0 | — |
| Cost of revenue | $7.43M | $5.37M | $2.47M | $555,000 | — |
| Gross profit | $252,000 | -$1.66M | -$1.31M | -$555,000 | — |
| R&D expense | $10.24M | $16.86M | $24.36M | $16.81M | $11.80M |
| SG&A expense | $19.05M | $26.02M | $37.34M | $34.69M | $18.41M |
| Operating income | -$29.04M | -$44.54M | -$63.01M | -$52.06M | -$40.71M |
| Interest expense | $3.52M | $3.02M | $2.91M | $30,000 | $775,000 |
| Pretax income | -$34.33M | -$48.48M | -$64.30M | -$59.40M | -$44.06M |
| Net income | -$33.25M | -$46.62M | -$60.24M | -$55.82M | -$43.18M |
| EBITDA | -$25.94M | -$41.54M | -$61.21M | -$51.46M | -$40.40M |
| EPS (basic) | -4.01 | -13.77 | -1.82 | -1.86 | -1.68 |
| EPS (diluted) | -4.01 | -13.77 | -1.82 | -1.86 | — |
| Weighted avg. shares (diluted) | 8.30M | 3.39M | 33.16M | 29.97M | — |
| Balance sheet | |||||
| Cash & equivalents | $6.74M | $4.67M | $11.38M | $29.16M | $80.24M |
| Short-term investments | $4.90M | $2.25M | $23.09M | $16.72M | — |
| Receivables | $1.09M | $710,000 | $319,000 | $420,000 | $322,000 |
| Inventory | $1.41M | $2.42M | $2.13M | $1.13M | $350,000 |
| Current assets | $24.77M | $16.02M | $43.94M | $59.41M | $92.94M |
| PP&E, net | $8.25M | $11.01M | $9.36M | $5.00M | $2.00M |
| Intangibles | $1.02M | $1.22M | $1.43M | $1.63M | $1.84M |
| Total assets | $35.38M | $30.06M | $56.96M | $68.75M | $99.20M |
| Current liabilities | $6.51M | $5.00M | $11.57M | $19.78M | $10.71M |
| Long-term debt | — | — | $17.50M | $200,000 | $200,000 |
| Total debt | — | — | $17.50M | $200,000 | $200,000 |
| Total liabilities | $29.18M | $15.72M | $29.77M | $26.72M | $20.99M |
| Shareholders' equity | $6.13M | $13.58M | $25.05M | $37.91M | $72.70M |
| Net debt | — | — | $6.12M | -$28.96M | -$80.04M |
| Shares outstanding | 589,639 | 4.13M | 45.90M | 30.74M | 29.89M |
| Cash flow statement | |||||
| Operating cash flow | -$18.14M | -$38.22M | -$56.01M | -$33.01M | -$23.13M |
| Capital expenditure | $1.02M | $5.88M | $5.75M | $3.88M | $1.38M |
| Free cash flow | -$19.17M | -$44.10M | -$61.76M | -$36.89M | -$24.51M |
| Investing cash flow | -$3.67M | $14.90M | -$12.23M | -$20.59M | -$1.45M |
| Financing cash flow | $29.09M | $16.65M | $43.17M | $2.70M | $79.45M |
| Depreciation & amortization | $3.10M | $3.00M | $1.80M | $600,000 | $314,000 |
| Stock-based compensation | $5.28M | $9.15M | $21.34M | $19.56M | $7.83M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.